EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps

Joshua S Jacobs iD, Joseph K Han, Jason K Lee, Tanya M Laidlaw, Nicole L Martin, Scott Caveney iD, Christopher S Ambrose iD, Neil Martin, Joseph D Spahn, Flavia C L Hoyte iD

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03006-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Joshua S Jacobs und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Asthma Clinical Research, 370 North Widget Lane, Suite 210, Walnut Creek, CA, 94598, USA. jjacobs@bayareaallergy.com. Hauptthemen laut MEDLINE: Asthma, Nasal Polyps, Sinusitis, Rhinitis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Tezepelumab blocks the activity of thymic stromal lymphopoietin, an epithelial cytokine implicated in the pathogenesis of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In a previous analysis, tezepelumab improved asthma and rhinosinusitis symptoms compared with placebo in patients with severe, uncontrolled asthma and a history of CRSwNP in the 2 years before randomization in the NAVIGATOR study. This post hoc analysis of patients with a CRSwNP diagnosis at any time before randomization in NAVIGATOR enabled domain and symptom-specific analyses of Sino-Nasal Outcome Test (SNOT)-22 outcomes. METHODS: Patients (aged 12-80 years) with severe, uncontrolled asthma were randomized to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. SNOT-22 total, domain, and item scores were assessed in patients with a history of CRSwNP. Annualized asthma exacerbation rate (primary efficacy outcome), pre-bronchodilator forced expiratory volume in 1 s, and Asthma Control Questionnaire-6, Asthma Quality of Life Questionnaire (standardized) for patients 12 years and older, and Asthma Symptom Diary scores were also assessed in patients with and without a history of CRSwNP. RESULTS: Of 1059 patients with severe asthma, 165 (15.6%) had a history of CRSwNP. Tezepelumab treatment resulted in sustained improvements versus placebo in SNOT-22 total score throughout the 52-week study period [least-squares mean difference (95% confidence interval) - 11.08 (- 17.80, - 4.35)]. Tezepelumab improved all five SNOT-22 domain scores (sleep, nasal, function, ear/facial, and emotion) and the five SNOT-22 item scores of most clinical interest (decreased sense of smell/taste, nasal blockage, reduced productivity, waking up tired, and cough). Tezepelumab improved asthma-related clinical outcomes in patients with and without a history of CRSwNP. CONCLUSION: In patients with severe, uncontrolled asthma and a history of CRSwNP, tezepelumab improved rhinosinusitis symptoms across multiple domains, as well as asthma exacerbations, lung function, asthma control, and health-related quality of life. GOV IDENTIFIER: NCT03347279 ( https://classic. CLINICALTRIALS: gov/ct2/show/NCT03347279 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaNasal PolypsSinusitisRhinitisAntibodies, Monoclonal, HumanizedHumansAdultMaleMiddle AgedFemaleAdolescentAgedChronic DiseaseYoung AdultSino-Nasal Outcome TestChildAged, 80 and overDouble-Blind MethodTreatment OutcomeSeverity of Illness IndexQuality of LifeRhinosinusitis

Stichwörter der Autor:innen

AsthmaBiologicChronic rhinosinusitisNasal polypsSino-Nasal Outcome Test-22TezepelumabThymic stromal lymphopoietin

Substanzen

Antibodies, Monoclonal, Humanizedtezepelumab

Autor:innen und Institutionen

  • Allergy and Asthma Clinical Research, 370 North Widget Lane, Suite 210, Walnut Creek, CA, 94598, USA. jjacobs@bayareaallergy.com.
  • Department of Otolaryngology & Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
  • Evidence Based Medical Educator Inc., Toronto, ON, Canada.
  • Toronto Allergy and Asthma Clinic, Toronto, ON, Canada.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Translational Immunology Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.

ORCID-Profile: Joshua S Jacobs, Scott Caveney, Christopher S Ambrose, Flavia C L Hoyte

Förderung

  • AstraZeneca
  • Amgen

Zitieren

APA

Jacobs, J. S., Han, J. K., Lee, J. K., Laidlaw, T. M., Martin, N. L., Caveney, S., Ambrose, C. S., Martin, N., Spahn, J. D., & Hoyte, F. C. L. (2025). Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps. Advances in Therapy. https://doi.org/10.1007/s12325-024-03006-5

Vancouver

Jacobs JS, Han JK, Lee JK, Laidlaw TM, Martin NL, Caveney S, et al. Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps. Advances in Therapy. 2025. doi:10.1007/s12325-024-03006-5

BibTeX
@article{Jacobs2025,
  author = {Jacobs, Joshua S and Han, Joseph K and Lee, Jason K and Laidlaw, Tanya M and Martin, Nicole L and Caveney, Scott and Ambrose, Christopher S and Martin, Neil and Spahn, Joseph D and Hoyte, Flavia C L},
  title = {Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03006-5}
}
Kostenlos starten →